Skip to main content

Find Clinical Trials

Home
Conditions
Urothelial Carcinoma (UC)

Clinical trial condition

Urothelial Carcinoma (UC)

Explore clinical trials studying Urothelial Carcinoma (UC). Study availability and eligibility vary by location and protocol.

24 public trials 13 recruiting studies

Refine in advanced search Browse all conditions

Urothelial Carcinoma (UC) trial results

Recruiting

Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma

NCT07441499

Conditions: Bladder (Urothelial, Transitional Cell) Cancer, Carcinoma, Carcinoma, Transitional Cell, +5 more
Locations: The second hospital of Tianjin Medical University Tianjin, China

View Trial Details

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT05706129

Conditions: Adenocarcinoma, Breast Diseases, Breast Neoplasms, +38 more
Locations: Peter MacCallum Cancer Centre Melbourne, Australia

UNSW Sydney, St Vincent's Hospital Sydney Sydney, Australia

Centre Jean Perrin Clermont-Ferrand, France

Centre Georges François Leclerc Dijon, France

View Trial Details

Recruiting

A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma

NCT06982794

Conditions: Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations: IRCCS San Raffaele Milan, Italy

View Trial Details

Enrolling by Invitation

Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

NCT07454941

Conditions: Carcinoma, Carcinoma, Transitional Cell, Diagnostic, +8 more
Locations: National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences Beijing Beijing, Chaoyang District, China

View Trial Details

Enrolling by Invitation

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

NCT07023848

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +16 more
Locations: Affiliated Hospital of Jiangnan University Wuxi, Jiangsu, China

View Trial Details

Enrolling by Invitation

The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

NCT07023861

Conditions: Breast Cancer, Breast Diseases, Breast Neoplasms, +16 more
Locations: Affiliated Hospital of Jiangnan University Wuxi, Jiangsu, China

View Trial Details

Not Yet Recruiting

FAPI PET Imaging - An Exploratory Study

NCT07705074

Conditions: Adenocarcinoma, Adenoma, Blood Protein Disorders, +80 more
Locations: Kantonsspital Baden Baden, Canton of Aargau, Switzerland

Hôpitaux Universitaires de Genève (HUG) Geneva, Canton of Geneva, Switzerland

Luzerner Kantonsspital Lucerne, Canton of Lucerne, Switzerland

Clinique de Genolier Genolier, Canton of Vaud, Switzerland

View Trial Details

Not Yet Recruiting

Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

NCT07643519

Conditions: Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +13 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

NCT07636772

Conditions: Carcinoma, Carcinoma, Transitional Cell, Neoplasms, +3 more
Locations: Fudan University Shanghai Cancer Center Shanghai, China

View Trial Details

Not Yet Recruiting

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

NCT07631884

Conditions: Advanced Malignant Solid Neoplasm, Biliary Tract Diseases, Biliary Tract Neoplasms, +56 more
Locations: Not specified

View Trial Details